Treatment with N-tosyl-l-phenylalanine chloromethyl ketone after the onset of collagen-induced arthritis reduces joint erosion and NF-κB activation

European Journal of Pharmacology

Volumn 595, Issue 1-3, 2008, Pages 108-113

  Choi, Jin ^a   Ha, Kyung Ho ^a   Byun, Mi Sun ^a   Min, So Youn ^a   Park, Min Jung ^a   Park, Hyun Sil ^a   Oh, Hye Joa ^a   Ju, Ji Hyeon ^a   Kim, Ho Youn ^a   Jue, Dae Myung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Collagen induced arthritis; Cytokine; Inflammation; NF B; Rheumatoid arthritis; Tosylphenylalanyl chloromethyl ketone

Indexed keywords

COLLAGEN TYPE 2; COLONY STIMULATING FACTOR 1; DRUG VEHICLE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE EROSION; BONE MARROW CELL; CELL PROLIFERATION; COLLAGEN INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; HISTOPATHOLOGY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LYMPHATIC DRAINAGE; MALE; MEDIATOR RELEASE; MOUSE; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; JOINTS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED DBA; NF-KAPPA B; OSTEOCLASTS; T-LYMPHOCYTES; TOSYLPHENYLALANYL CHLOROMETHYL KETONE;

EID: 52049102623     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.056     Document Type: Article

References (36)

1. Alkalay I., Yaron A., Hatzubai A., Jung S., Avraham A., Gerlitz O., Pashut-Lavon I., and Ben-Neriah Y. In vivo stimulation of IκB phosphorylation is not sufficient to activate NF-κB. Mol. Cell. Biol. 15 (1995) 1294-1301
2. Barnes P.J., and Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336 (1997) 1066-1071
3. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
4. Byun M.S., Jeon K.I., Choi J.W., Shim J.Y., and Jue D.M. Dual effect of oxidative stress on NF-κB activation in HeLa cells. Exp. Mol. Med. 34 (2002) 332-339
5. Chiao P.J., Miyamoto S., and Verma I.M. Autoregulation of IκBα activity. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 28-32
6. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344 (2001) 907-916
7. Clohisy J.C., Roy B.C., Biondo C., Frazier E., Willis D., Teitelbaum S.L., and Abu-Amer Y. Direct inhibition of NF-κB blocks bone erosion associated with inflammatory arthritis. J. Immunol. 171 (2003) 5547-5553
8. DiDonato J.A., Mercurio F., and Karin M. Phosphorylation of IκBα precedes but is not sufficient for its dissociation from NF-κB. Mol. Cell. Biol. 15 (1995) 1302-1311
9. Finco T.S., Beg A.A., and Baldwin A.S. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 11884-11888
10. Firestein G.S. NF-κB: holy grail for rheumatoid arthritis. Arthritis Rheum. 50 (2004) 2381-2386
11. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., Leonardi A., Tran T., Boyce B.F., and Siebenlist U. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11 (1997) 3482-3496
12. Gerlag D.M., Ransone L., Tak P.P., Han Z., Palanki M., Barbosa M.S., Boyle D., Manning A.M., and Firestein G.S. The effect of a T cell-specific NF-κB inhibitor on in vitro cytokine production and collagen-induced arthritis. J. Immunol. 165 (2000) 1652-1658
13. Griscavage J.M., Wilk S., and Ignarro L.J. Serine and cysteine proteinase inhibitors prevent nitric oxide production by activated macrophages by interfering with transcription of the inducible NO synthase gene. Biochem. Biophys. Res. Commun. 215 (1995) 721-729
14. Guesdon F., Ikebe T., Stylianou E., Warwick-Davies J., Haskill S., and Saklatvala J. Interleukin 1-induced phosphorylation of MAD3, the major inhibitor of nuclear factor κB of HeLa cells. Interference in signalling by the proteinase inhibitors 3,4-dichloroisocoumarin and tosylphenylalanyl chloromethylketone. Biochem. J. 307 (1995) 287-295
15. Han Z., Boyle D.L., Manning A.M., and Firestein G.S. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28 (1998) 197-208
16. Handel M.L., McMorrow L.B., and Gravallese E.M. Nuclear factor-κB in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum. 38 (1995) 1762-1770
17. Henkel T., Machleidt T., Alkalay I., Kronke M., Ben-Neriah Y., and Baeuerle P.A. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 365 (1993) 182-185
18. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3 (1997) 1285-1289
19. Jimi E., Aoki K., Saito H., D'Acquisto F., May M.J., and Nakamura I. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10 (2004) 617-624
20. Jue D.M., Jeon K.I., and Jeong J.Y. Nuclear factor κB (NF-κB) pathway as a therapeutic target in rheumatoid arthritis. J. Korean Med. Sci. 14 (1999) 231-238
21. Kim K.U., Kwon O.J., and Jue D.M. Pro-tumour necrosis factor cleavage enzyme in macrophage membrane/particulate. Immunology 80 (1993) 134-139
22. Kim H., Lee H.S., Chang K.T., Ko T.H., Baek K.J., and Kwon N.S. Chloromethyl ketones block induction of nitric oxide synthase in murine macrophages by preventing activation of nuclear factor-κB. J. Immunol. 154 (1995) 4741-4748
23. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S., Wong T., Campagnuolo G., Moran E., Bogoch E.R., Van G., Nguyen L.T., Ohashi P.S., Lacey D.L., Fish E., Boyle W.J., and Penninger J.M. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
24. LeBlanc M.H., Feng Y., and Fratkin J.D. N-tosyl-l-phenylalanyl-chloromethylketone reduces hypoxic-ischemic brain injury in rat pups. Eur. J. Pharmacol. 390 (2000) 249-256
25. Mackman N. Protease inhibitors block lipopolysaccharide induction of tissue factor gene expression in human monocytic cells by preventing activation of c-Rel/p65 heterodimers. J. Biol. Chem. 269 (1994) 26363-26367
26. Marok R., Winyard P.G., Coumbe A., Kus M.L., Gaffney K., Blades S., Mapp P.I., Morris C.J., Blake D.R., Kaltschmidt C., and Baeuerle P.A. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum. 39 (1996) 583-591
27. Mellits K.H., Hay R.T., and Goodbourn S. Proteolytic degradation of MAD3 (IκBα) and enhanced processing of the NF-κB precursor p105 are obligatory steps in the activation of NF-κB. Nucleic Acids Res. 21 (1993) 5059-5066
28. Min S.Y., Hwang S.Y., Park K.S., Lee J.S., Lee K.E., Kim K.W., Jung Y.O., Koh H.J., Do J.H., Kim H., and Kim H.Y. Induction of IL-10-producing CD4+CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res. Ther. 6 (2004) R213-219
29. Miyamoto S., Maki M., Schmitt M.J., Hatanaka M., and Verma I.M. Tumor necrosis factor α-induced phosphorylation of IκBα is a signal for its degradation but not dissociation from NF-κB. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12740-12744
30. Myers L.K., Rosloniec E.F., Cremer M.A., and Kang A.H. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61 (1997) 1861-1878
31. Plater-Zyberk C., Joosten L.A., Helsen M.M., Sattonnet-Roche P., Siegfried C., Alouani S., van De Loo F.A., Graber P., Aloni S., Cirillo R., Lubberts E., Dinarello C.A., van Den Berg W.B., and Chvatchko Y. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. 108 (2001) 1825-1832
32. Rovin B.H., Dickerson J.A., Tan L.C., and Hebert C.A. Activation of nuclear factor-κB correlates with MCP-1 expression by human mesangial cells. Kidney Int. 48 (1995) 1263-1271
33. Ruocco M.G., Maeda S., Park J.M., Lawrence T., Hsu L.C., Cao Y., Schett G., Wagner E.F., and Karin M. IκB kinase (IKK) β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201 (2005) 1677-1687
34. Sugatani T., Alvarez U.M., and Hruska K.A. Activin A stimulates IκB-α/NF-κB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J. Cell. Biochem. 90 (2003) 59-67
35. Thornton S., Duwel L.E., Boivin G.P., Ma Y., and Hirsch R. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum. 42 (1999) 1109-1118
36. van den Berg W.B. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res. 3 (2001) 18-26